相关实验视频

Updated: May 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

基于模型的放射性药物治疗优化:关于PBPK模型参数对Lu-PSMA治疗中的物理,生物和统计测量的影响的研究177

Hamid Abdollahi^1,2, Ali Fele-Paranj^2,3, Arman Rahmim^1,2,4

¹Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.

|September 28, 2024

概括

基于生理学上的药理动力学 (PBPK) 参数显著影响着针对前列腺特异性膜抗原 (PSMA) 的卢铁-177放射性药物疗法 (RPT). 优化这些参数可以提高RPT的疗效,并个性化治疗以改善治疗结果.

科学领域:

核医学是一种核医学.
放射性药物疗法是一种放射性药物疗法.
药理动力学药理动力学

背景情况:

177标记的放射性药物疗法 (RPT) 针对前列腺特异性膜抗原 (PSMA) 对于前列腺癌治疗至关重要.
基于生理学的药理动力学 (PBPK) 模型提供了一个框架,以了解药物在体内的行为.
评估PBPK参数对治疗结果的影响对于治疗优化至关重要.

研究的目的:

调查PBPK参数如何影响PSMA向的177Lu-RPTs中的物理,生物和统计测量.
评估参数变化对剂量计算的影响,包括生物有效剂量 (BED).
为个性化RPT疗法和最大限度地减少毒性提供见解.

主要方法:

利用临床验证的PBPK模型生成瘤和关键器官 (唾液腺,脏) 的时间活动曲线 (TAC).
计算了关键的剂量计量指标:TAC下的面积 (AUC),吸收剂量,BED和BED (fBED).
系统地操纵PBPK参数,以评估它们对放射生物和药物动力学特征的影响.

主要成果:

在四个BED模型中,PBPK参数操纵显著改变了AUC,剂量,BED和fBED.
增加的关联率增强了瘤吸收和BED,对非点器官的影响最小.
内化和血清蛋白结合率影响了瘤和脏剂量,而瘤受体密度和连接体量影响了吸收.
瘤体积和释放率的调整对于优化向和最大限度地减少非向毒性至关重要.

结论:

优化PBPK参数是提高177Lu-PSMA RPTs疗效的关键.
PBPK建模为开发个性化治疗策略提供了宝贵的见解.
微调PBPK参数可以改善治疗结果,并减少PSMA向RPT中的毒性.

关键词:

生物有效剂量的生物有效剂量.转移性割抵抗性前列腺癌基于生理学的药物动力学模型.放射生物学的反应放射性药物疗法是一种放射性药物疗法.

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...